How Should One Decide Whom to Treat for Hypertension? Ppt Powerpoint Presentation slides Jay N. Cohn, M.D. Medical Slideshow To whom all hearts are open, All desires known, and from whom no secrets ar

How Should One Decide Whom to Treat for Hypertension?

Rating :

Rate It:

Send This

Download

Comment

Favourite

more

Post To:

Facebook

Twitter

Digg

Delicious

more share options

There is no comments now for this Slide.

Post a comment

Post Comment on Twitter Post Comment on SlideWorld

Comments:

Subscribe to follow-up comments

Notes

Show Notes

Slide 1 :

How Should One Decide Whom to Treat for Hypertension? Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota Medical School Minneapolis, MN

Slide 2 :

CV Mortality Risk Doubles withEach 20/10 mm Hg BP Increment* *Individuals aged 40-69 years, starting at BP 115/75 mm Hg. CV, cardiovascular; SBP, systolic blood pressure; DBP, diastolic blood pressure Lewington S, et al. Lancet. 2002; 60:1903-1913. JNC VII. JAMA. 2003. CVmortalityrisk SBP/DBP (mm Hg) 0 1 2 3 4 5 6 7 8 115/75 135/85 155/95 175/105

Slide 3 :

Impact of “High-Normal” BP on CV RiskData from the Framingham Heart Study 16 12 8 4 0 Optimal BP Normal BP 12 8 4 0 0 2 4 6 8 10 12 Years Optimal BP Normal BP High-normal BP Women Men Cumulative incidence of CV events (%) High-normal BP Vasan et al. N Engl J Med. 2001;345:1291-7. Optimal BP: <120/80 Normal BP: 120-129/80-84 High-normal BP: 130-139/85-89

Slide :

Slide 5 :

Hypothesis The apparent linear relationship between blood pressure and ischemic disease events as well as age and ischemic disease events does not necessarily mean that age or blood pressure cause events but that both markers capture a progressively higher proportion of people with early disease.

Slide 6 :

Blood Pressure and Likelihood of Disease 100 Frequency in Population (%) 50 0 75 100 125 150 175 200 Systolic Blood Pressure (mmHg) No Disease Possible Disease Likely Disease

Slide 7 :

Systolic BP Reduction and CVD Mortality ? Systolic BP (control - experimental, mm Hg) Cardiovascular Mortality Odds Ratio Staessen JA et al. Lancet. 2001;358:1305 -1315.

Slide 8 :

SBP Reductions as Little as 2 mm Hg Reduce the Risk of CV Events by Up to 10% Meta-analysis of 61 prospective, observational studies 1 million adults 12.7 million person-years Lewington S et al. Lancet. 2002;360:1903-1913. 2 mm Hg decrease in mean SBP 10% reduction in risk of stroke mortality 7% reduction in risk of ischemic heart disease mortality

Slide :

Slide 10 :

Hypothesis The apparent linear relationship between the magnitude of drug-induced BP fall and the reduction of morbid events does not necessarily indicate that blood pressure reduction prevents events but that the drugs protect the arteries and heart (while also lowering blood pressure). A corollary: the greater the BP reduction from a drug the less the vascular disease - i.e., BP fall identifies a low-risk population.

Slide 11 :

Antihypertensive Drugs that Slow Disease Progression in Known Doses Vascular Cardiac Ramipril Enalapril Perindopril Captopril ?other ACEIs Carvedilol Amlodipine Metoprolol Valsartan Bucindolol Losartan Valsartan Hydrochlorothiazide Candesartan Spironolactone Eplerenone ISDN/hydralazine

Slide 12 :

Old Paradigm BP Cholesterol Disease Disease Treatment Treatment Normal Normal GOAL: Target Response

Slide 13 :

Current Paradigm DISEASE BP Cholesterol GOAL: ?Target Response TREATMENT

Slide 14 :

Pathophysiology of CV Continuum Genes Environment Ethnicity Diet Family Hx Exercise Polymorphisms Stress Proteomics Smoking Blood Vessel/ Heart Angiotensin Nitric Oxide Progression Aldosterone Norepinephrine Cytokines Structural Remodeling CAD Cerebrovascular Disease Heart Failure Renal Failure PVD Dementia

Slide 15 :

Genes, Ethnicity, Diet, Exercise, Smoking, Obesity, Lipids Small Artery Arterial Structural Cardiac Elasticity Abnormalities Abnormalities (Endothelial Microalbumin LVM Dysfunction) IMT BNP BP Retinal Vasculopathy ECG PNE Large Artery Elasticity AngII Exercise BP Resting BP Disease Drug Therapy RAAS Blockade Statins NO Enhancers Antihypertensives Antioxidants ?Antiinflammatories

Slide 16 :

ASH Writing Group: Proposed New Definition of Hypertension Hypertension is a progressive cardiovascular syndrome arising from complex and interrelated etiologies. Early markers of the syndrome are often present before blood pressure elevation is sustained; therefore, hypertension cannot be classified solely by discrete blood pressure thresholds. Progression is strongly associated with functional and structural cardiac and vascular abnormalities that damage the heart, kidneys, brain, vasculature and other organs and lead to premature morbidity and death. ASH Writing Group 2005.

Slide 17 :

†CVD designation is determined by the constellation of risk factors, early disease markers, and target-organ disease. CVD, cardiovascular disease. ASH Writing Group Definition and Classification of Hypertension ASH Writing Group 2005.

Slide 18 :

Early Markers for Hypertensive Vascular Disease Blood Pressure -Exaggerated response to exercise -Widened pulse pressure Vascular -Reduced small artery elasticity -Reduced large artery elasticity -Endothelial dysfunction -Increased pulsewave velocity -Increased carotid intima-medial thickness -Retinal vascular changes -Microalbuminuria Cardiac -Increased LV wall thickness -Increased LV volume -Increased LV mass -Abnormal ECG -B-type natriuretic peptide

Slide 19 :

R A S M U S S E NC E N T E RforCARDIOVASCULARDISEASE PREVENTION

Slide 20 :

RASMUSSEN CENTER Screening Tests for Early Detection Arterial Elasticity (Pulse Contour Analysis) - Small Artery (C2) - Large Artery (C1) Rest and exercise BP (3-minute treadmill) Retinal digital photograph Urine for microalbumin/creatinine ratio Carotid intimal-medial thickness Vascular Evaluation

Slide 21 :

RASMUSSEN CENTER Screening Tests for Early Detection Cardiac Evaluation Electrocardiogram Cardiac ultrasound (LVID & LVWT) Plasma BNP (Biosite)

Slide 22 :

RASMUSSEN CENTER Screening Tests for Early Detection Modifiable Disease Contributors Fasting lipids (LDL, HDL, Trig) Fasting blood sugar hsCRP Homocysteine

Slide 23 :

Results of Rasmussen Center Screening Frequency Rasmussen Score Low Risk 33% Modest Risk 36% High Risk 31%

Slide 24 :

Patient: 60-year-old female registered nurse Past History: negative except high cholesterol Family History: both parents smoked, no significant CV disease Physical Exam: Height 5’4” Weight 126 lb. HR 64 b/min BP 132/66 mmHg Screening Results: C1 = 8.5 ml/mmHg x10 (abnormal) C2 = 2.4 ml/mmHg x100 (abnormal) Exercise BP = 173/64 mmHg (abnormal) Retinal photo = A:V nicking (abnormal) Microalbumin = 0.86 mg/mmol (abnormal) LV ultrasound = increased mass (abnormal) Rasmussen score = 12 points Blood Chemistry: LDL 187 mg/dl; HDL 70 mg/dl Interpretation: Advanced CV Disease Treatment: Antihypertensive, statin

Slide 25 :

Patient: 62-year-old female florist Past History: Asymptomatic, plays tennis and golf Elevated cholesterol: Atorvastatin, 10 mg Family History: Negative Physical Exam: Height 5’5” Weight 128 lb. HR 74 b/min BP 140/80 mmHg Screening Results: C1 = 8.7 ml/mmHg x10 (abnormal) C2 = 1.6 ml/mmHg x100 (abnormal) Exercise BP = 182/80 mmHg (abnormal) Retinal photo = decreased A:V ratio (borderline) Microalbumin = 1.98 mg/mmol (abnormal) Rasmussen score = 9 points Blood Chemistry: LDL 137 mg/dl; HDL 129 mg/dl; CRP 0.13 mg/dl Interpretation: Advancing CV Disease Treatment: ACE/ARB; BP Control; Increase atorvastatin

Slide 26 :

Patient: 49-year-old male executive Past History: Overweight, elevated BP, asymptomatic, no therapy Family History: Hypertension, coronary disease Physical Exam: Height 5’8” Weight 240 lb. HR 76 b/min BP 144/84 mmHg Screening Results: C1 = 16.1 ml/mmHg x10 (normal) C2 = 6.4 ml/mmHg x100 (normal) Exercise BP = 154/74 mmHg (normal) All other tests normal Rasmussen score = 2 points (BP only) Blood Chemistry: LDL 172 mg/dl; HDL 38 mg/dl; FBS 108 mg/dl; CRP 1.0 mg/dl Interpretation: No CV Disease Treatment: Diet, ?statin

Slide 27 :

Strategies for Aggressive Treatment PRIMARY PREVENTION Primary Prevention (global) Polypill Everyone >55 years old Impractical Inefficient Benefit: risk ratio untested Primary Prevention (targeted) Risk factor identification Treatment targets risk factor Misses many at-risk Risk factor levels? Benefit: risk?

Slide 28 :

Strategies for Aggressive Treatment SECONDARY PREVENTION Secondary Prevention (early) Detect markers for early disease Treat disease not risk factor Sensitivity/specificity of detection? Benefit: risk better? Prolonged event-free survival Reduced health care costs Secondary Prevention (late) Patients with symptomatic disease Treatment can prevent events/prolong life Increased burden of health care costs

Slide 29 :

Risk Factors Biomarkers Cardiac and Vascular Structural Abnormalities Death Non-Fatal Morbid Events Recurrence Progression Primary Prevention Secondary Prevention Tertiary Prevention

Slide 30 :

Who to Treat with Antihypertensives (Pressure Orientation) SBP>160 mmHg most of the time SBP>140 mmHg most of the time & evidence for vascular or cardiac functional/structural abnormalities SBP>130 mmHg with symptomatic vascular or cardiac disease or diabetes ?SBP>130 mmHg with evidence for vascular or cardiac functional/structural abnormalities GOAL: Lower Blood Pressure

Slide 31 :

Who to Treat with Antihypertensives (Pathophysiologic Orientation) Anyone with symptomatic atherosclerotic vascular or cardiac disease ?Anyone with vascular or cardiac functional/structural abnormalities and BP >120/80 mmHg GOAL: Slow Disease Progression

Slide 32 :

Future Paradigm Early Disease Statin RAAS Blockade Antihypertensives NO donor/enhancer Innovative Therapy Slow Progression GOAL: ?Target Dose

Slide 33 :

Strategies to Identify At-Risk Population Blood pressure level Which measurement? What level? Cholesterol level Which fraction? Reproducibility? Blood pressure + cholesterol (BP + Ch) Sensitivity, specificity BP + Ch + other “risk factors” Sensitivity, specificity Early disease detection Endothelial dysfunction Vascular functional/structural abnormalities Cardiac functional/structural abnormalities

	Medslides_PPT 1 Years ago. Category: Internal Medicine

Tags:	Internal Medicine

Embed:
1225 Views, 0 favourite
PowerPoint Presentation on How Should One Decide Whom to Treat for Hypertension? or PowerPoint Pres more PowerPoint Presentation on How Should One Decide Whom to Treat for Hypertension? or PowerPoint Presentation on Hypertension less

SWINE Flu

Why do women live longer then men? Humor

History of Medicine

Yoga and Medicine

How to be a Successful Interventional Fellow size 50 MB

Cardiac Pathology

Hypertension: New Concepts, Guidelines, and Clinical Management

Diabetes Pathology

Medical Powerpoint Templates
(20% Dicsount For Student/Faculty)